Does the NHS fund ACI?

The NHS does fund ACI — but with meaningful conditions attached. A 2017 NICE ruling (Technology Appraisal 477) made ACI and its matrix-based derivative MACI the only cell-based cartilage repair techniques commissioned by the NHS for knee defects. No other approach of this type has been approved since, which means newer single-stage options such as STACi sit entirely outside NHS commissioning and are available only privately.

Access is not automatic. Funding depends on a patient meeting all eligibility criteria at once: the defect must exceed 2 cm², there must be minimal osteoarthritic change, no previous cartilage repair surgery should have been performed on that knee, and treatment must take place at a designated tertiary referral centre. Many patients with knee cartilage problems fall outside one or more of these gates — and for them, the NHS route is not currently open.

Who qualifies under the NHS criteria

Four conditions must all be satisfied simultaneously for NHS funding to apply — missing any one of them closes the TA477 route.

• The defect is larger than 2 cm². Smaller lesions fall outside the scope of TA477; simpler techniques are usually considered appropriate for them.
• There is minimal arthritis in the knee. Moderate or widespread osteoarthritic change is a disqualifier. NICE is specifically looking for a focal defect in an otherwise reasonably healthy joint.
• No previous cartilage repair surgery on that knee. A prior microfracture, OATS, or ACI attempt on the same knee removes eligibility under this guidance, regardless of how long ago it was performed.
• Treatment must be carried out at a designated NHS tertiary referral centre. ACI cannot be accessed through a general district hospital under this funding route.

NICE drew these criteria deliberately narrowly. The guidance committee's own cost-effectiveness modelling found ACI most likely to fall under the £20,000-per-QALY threshold specifically in patients with no history of cartilage surgery and only minimal arthritis — the subgroup with the greatest biological potential for successful repair. Approving it more broadly would have taken the cost-effectiveness estimate into uncertain territory.

Patients who do not meet one or more of these conditions are not without options. Private funding and alternative techniques — including single-stage approaches not covered by TA477 — remain available; costs and choices are set out in the sections that follow.

Where NHS ACI is actually performed

Three hospitals hold designated NHS tertiary centre status for ACI: the Robert Jones and Agnes Hunt Orthopaedic Hospital (RJAH) in Oswestry, the Royal National Orthopaedic Hospital (RNOH) in Stanmore, and University Hospital Southampton. For patients in Lincolnshire, the East Midlands, or the wider East of England, Oswestry is typically the nearest commissioned option.

RJAH carries the longest track record of the three. The hospital ran ACI clinical trials for roughly 20 years before the procedure received NICE approval in October 2017, working alongside Keele University and operating its own dedicated Oscell Cell Manufacturing Facility for the laboratory cell-culture stage. That depth of experience is clinically relevant: in a technically demanding two-stage procedure, surgical volume and team familiarity matter.

Travel is a practical consideration worth factoring in early. Because ACI involves two separate hospital visits — an arthroscopic harvest and, several weeks later, the implantation procedure — patients travelling from Lincolnshire to Oswestry face that journey more than once. Recovery to everyday activities typically takes around three months, so patients should also plan for time away from work across both procedures and the intensive rehabilitation that follows, not just around a single operation date.

Waiting times at NHS tertiary centres are not standardised and tend to run into months rather than weeks — specialty referral pathways rarely move quickly, and ACI is no exception. A referring GP or consultant can give a current estimate for the relevant centre, as waiting periods shift with referral volume and seasonal demand. For patients who cannot wait, or whose clinical profile sits outside the TA477 criteria, private care offers an alternative worth exploring.

What two-stage ACI and MACI cost privately

Private two-stage MACI or ACI carries a substantial price tag. The total cost typically falls in the £20,000–£40,000 range, with the laboratory cell-culturing stage — where harvested chondrocytes are expanded over several weeks before reimplantation — accounting for £10,000–£17,000 of that figure alone. London Cartilage Clinic, one of the few UK specialist centres offering the procedure privately, quotes the two-stage MACI range at £25,000–£35,000, and notes that costs frequently run higher; prices vary by centre, surgeon experience, and the clinical complexity of each case.

What those headline figures typically do not include is equally important:

• Anaesthetist fees — charged separately for each of the two operations
• Overnight hospital stays (one per procedure for most patients)
• Pre- and post-operative MRI imaging
• Mandatory post-operative physiotherapy

Each item can add meaningfully to the bill. The gap between the lowest and highest private quotes often lies precisely in what is or is not bundled, which is why comparing headline numbers between providers can be misleading.

The laboratory stage is the largest single structural cost driver and applies at every specialist centre performing the procedure — it reflects the manufacturing complexity of culturing living cells under pharmaceutical-grade conditions for several weeks, independent of surgical fees.

Anyone considering private two-stage MACI or ACI should ask any potential provider for a fully itemised quote before committing. A clear breakdown — surgery, laboratory, hospital facility, anaesthesia, imaging, and rehabilitation — is the only reliable basis for comparison.

For patients who do not meet the NHS TA477 criteria and find these costs prohibitive, the single-stage STACi option is worth understanding as an alternative: it is addressed in the following section.

STACi as a private single-stage alternative

Collapsing a two-stage procedure into a single operation is the central idea behind STACi — single-treatment autologous chondrocyte implantation. Rather than harvesting cartilage cells, sending them to a laboratory for several weeks of culture, and then returning for a second procedure, STACi combines biopsy and reimplantation in one visit, eliminating the cell-manufacturing lag and reducing the overall treatment burden.

That streamlined process accounts for much of the price difference. London Cartilage Clinic lists STACi at approximately £12,500 all-inclusive — a guide figure that represents a meaningful reduction against the £25,000–£35,000 bracket for two-stage MACI. It is a private-only pathway; STACi currently sits outside NICE TA477 and is not NHS-commissioned.

In terms of patient profile, the technique tends to suit younger, active individuals — typically under 40 to 45 — who have a discrete focal defect without widespread joint arthritis. Where OA is more diffuse, neither STACi nor conventional ACI variants is likely to be appropriate.

The evidence base is still maturing. STACi is an emerging approach with a growing but limited long-term dataset compared with first- and second-generation ACI; Taylor and Lee's 2019 paper on next-generation single-treatment ACI set out the biological rationale and early clinical findings, but the decades of follow-up that underpin conventional ACI do not yet exist for its single-stage successor. The cost difference is real, but it reflects a different biological approach as much as a simpler procedure. A proper clinical assessment — rather than price comparison alone — is the right basis for choosing between the two pathways.

Getting assessed and making the decision

The starting point, regardless of which route a patient pursues, is an accurate MRI assessment: defect size and the extent of any osteoarthritic change are the two variables that shape NHS eligibility and guide the choice between private options.

For patients who believe they meet all four TA477 criteria outlined in the earlier sections, the practical first move is asking a GP for a referral to one of the designated tertiary centres. Referrals from outside a centre's usual geographic catchment are accepted; a GP letter is the only formality required to begin that process.

For those who fall outside the criteria — or who want to explore options without a waiting list — private consultants can be seen directly, without a GP letter. When requesting a quote at any provider, ask for a fully itemised breakdown: surgery, laboratory cell-culturing, anaesthesia, hospital facility, imaging, and rehabilitation listed separately. As discussed above, the gap between the lowest and highest private figures often lies precisely in what is or is not bundled.

The right decision between NHS ACI, private MACI, STACi, or an alternative approach depends on a proper clinical assessment of an individual's imaging and history rather than cost comparison alone. MSK Doctors consultants can review MRI findings and discuss all relevant options without a GP referral or NHS waiting list; appointments can be booked at mskdoctors.com.